Why carry out this study?

Plaque psoriasis in high-impact areas, including the scalp, nails, palms, and soles, can disproportionately impair the health-related quality of life of patients. Therefore, the efficacy of biologic treatments in these areas is of considerable interest to patients and physicians.

This study evaluated the 2-year efficacy of bimekizumab treatment in patients with moderate to severe plaque psoriasis in post hoc analyses of five phase 3/3b trials.

What was learned from the study?

Bimekizumab-treated patients showed high efficacy responses in these high-impact areas, which were sustained over 2 years.

Bimekizumab can provide a lasting treatment option for patients with psoriasis affecting high-impact areas.